IDT Australia : Resignation of Managing Director

RESIGNATION OF MANAGING DIRECTOR

14 July 2017, Melbourne: (ASX: IDT): The Managing Director of IDT, Dr Paul MacLeman, has advised the Board of his intention to resign from the position to advance new business initiatives and to pursue further non‐executive board roles. To allow an orderly transition his resignation as CEO will take effect from 31st August 2017. Dr MacLeman will resign from the Board as at close of business today.

The Chairman, Mr Graeme Kaufman, thanked Paul for his contribution to the development of IDT, noting "With his strong background in corporate strategy, Paul correctly identified the limited growth opportunities in IDT's traditional markets and the need to capture more of the value chain, leading to the development of our generics business. We will miss him, and wish him well in his future endeavours."

The Board is undertaking a search for a replacement.

ENDS

For further information please contact: Graeme Kaufman (Chairman) 0409 013 063

About IDT IDT Australia Ltd recently acquired a portfolio of 23 generic drugs to manufacture and sell via US distribution partners. With IDT's 2013 Temozolomide ANDA filing this signifies IDT's move to rapidly become a specialty generics business with near term revenue build up.

IDT (ASX:IDT) is a public Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. It has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are fully cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world‐class facilities, IDT provides a full‐scale service for new drug development and scale‐up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.

Appendix 3Z Final Director's Interest Notice Appendix 3Z

Final Director's Interest Notice

Rule 3.19A.3

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity IDT Australia Ltd

ABN 66 006 522 970

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Paul MacLeman
Date of last notice	30 November 2015
Date that director ceased to be director	14 July 2017

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities

4,071,000 Ordinary Shares

+ See chapter 19 for defined terms.

11/3/2002 Appendix 3Z Page 1

Appendix 3Z Final Director's Interest Notice

Part 2 - Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest

Note: Provide details of the circumstances giving rise to the relevant interest

Nil

Number & class of securities

Part 3 - Director's interests in contracts

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
No. and class of securities to which interest relates	n/a

+ See chapter 19 for defined terms.

Appendix 3Z Page 2 11/3/2002